Erica Hong

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Xiuxia Sun, Jose F. Ponte, Nicholas C. Yoder et al. · Bioconjugate Chemistry · 2017 · 253 citations

Pharmacy, Oncology, Pharmacology +17

Preclinical Antitumor Activity of a Novel Anti–c-KIT Antibody–Drug Conjugate against Mutant and Wild-type c-KIT–Positive Solid Tumors

Tinya J. Abrams, Anu Connor, Christie Fanton et al. · Clinical Cancer Research · 2018 · 66 citations

Medicine, Oncology, Pharmacology +15

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation

Erica Hong, Hans K. Erickson, Robert J. Lutz et al. · Molecular Pharmaceutics · 2015 · 51 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing

Wayne C. Widdison, Jose F. Ponte, Jennifer A. Coccia et al. · Bioconjugate Chemistry · 2015 · 38 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells

Rajeeva Singh, Yulius Y. Setiady, Jose F. Ponte et al. · Molecular Cancer Therapeutics · 2016 · 36 citations

Pharmacy, Oncology, Pharmacology +17